Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial

OBJECTIVE: To examine the efficacy and safety of TAS5315, an irreversible covalent Bruton’s tyrosine kinase inhibitor, in Japanese patients with rheumatoid arthritis (RA) refractory to methotrexate. METHODS: In part A of this phase IIa double-blind study, patients were randomised to TAS5315 4 or 2 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Sakae, Murata, Mitsuru, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359550/
https://www.ncbi.nlm.nih.gov/pubmed/37217273
http://dx.doi.org/10.1136/ard-2022-223759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359550/
https://www.ncbi.nlm.nih.gov/pubmed/37217273
http://dx.doi.org/10.1136/ard-2022-223759

Ejemplares similares